The Delta:Notch signaling pathway regulates numerous aspects of differentiation, morphogenesis and cell function, during embryogenesis and throughout adult life. More recently, Delta-like 4 (Dll4) has been shown to regulate adult neo-vascularization (angiogenesis). Consequently, therapeutic strategies to target Dll4 have been put forward for the treatment of different cancers. In the present study, we describe for the first time that Dll4 blockade affects the bone marrow (BM) microenvironment, by perturbing the BM vascular niche. Anti-Dll4 treatment administered 1 day after myeloablation increased the BM vascular content (CD31+ cells), promoted megakaryopoiesis and promoted hematopoietic (Sca1+) and endothelial progenitor (Flk1+CXCR4+) cell mobilization to the peripheral blood (PB). Moreover, anti-Dll4 treatment increased BM myeloid content, and induced mobilization of B (B220hiCD19lo) and T (CD3+NK1.1-) lymphocytes to the PB. Taken together, we show that Dll4 blockade affects the BM vascular niche, and as such affects hematopoietic cell differentiation and mobilization.
. 2010 Sep 24;4(Suppl 2):P38.
Dll4 blockade interferes with the bone marrow vascular niche and perturbs hematopoietic recovery following myeloablation
Leonor Remédio
1,2,3,✉, Tânia Carvalho
1,2,3, Sérgio Dias
1,2,3
Leonor Remédio
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE, Lisbon, Portugal
2CEDOC, FCM, Universidade Nova de Lisboa, Lisbon, Portugal
3Instituto Gulbenkian de Ciência, Oeiras, Portugal
Find articles by Leonor Remédio
Tânia Carvalho
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE, Lisbon, Portugal
2CEDOC, FCM, Universidade Nova de Lisboa, Lisbon, Portugal
3Instituto Gulbenkian de Ciência, Oeiras, Portugal
Find articles by Tânia Carvalho
Sérgio Dias
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE, Lisbon, Portugal
2CEDOC, FCM, Universidade Nova de Lisboa, Lisbon, Portugal
3Instituto Gulbenkian de Ciência, Oeiras, Portugal
Find articles by Sérgio Dias
1Angiogenesis Lab, CIPM, Portuguese Institute of Oncology, IPOFG, EPE, Lisbon, Portugal
2CEDOC, FCM, Universidade Nova de Lisboa, Lisbon, Portugal
3Instituto Gulbenkian de Ciência, Oeiras, Portugal
✉
Corresponding author.
Supplement
Abstracts of the 16th International Charles Heidelberger Symposium on Cancer ResearchAna M Urbano, A J Guiomar, Carlos F Oliveira, Isabel M Carreira and Maria C AlpoimThe 16th International Charles Heidelberger Symposium on Cancer Research thanks ACIMAGO, BPI, FCT, FLAD, Pfizer, Fundação Champalimaud, Alfagene, Reagente 5 and Câmara Municipal de Montemor o Velho who sponsor this Symposium.http://www.biomedcentral.com/content/pdf/1753-6561-4-S2-info.pdf
Conference
26-28 September 2010
16th International Charles Heidelberger Symposium on Cancer Research
Coimbra, Portugal
Collection date 2010.
Copyright ©2010 Remédio et al; licensee BioMed Central Ltd.
PMCID: PMC3255035
